You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Influenza Across the Ages: Tailoring Antiviral Therapy and Prophylaxis

  • Authors: Charles Vega, MD; Jeff Goad, PharmD, MPH, FAPhA, FISTM, CTH; Ravi Jhaveri, MD; Andrew Pavia, MD; Ruth Carrico, PhD, DNP, APRN, CIC, FSHEA, FNAP, FAAN
  • CME / ABIM MOC / CE Released: 7/13/2022
  • Valid for credit through: 7/13/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, pediatricians, obstetricians, gynecologists, and emergency medicine physicians.

The goal of this activity is to improve clinicians’ understanding of data on antiviral therapy and prophylaxis for flu from infant to older adults, providing expert perspectives and interpretation for practical application.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Data on the impact of antivirals for influenza and associated healthcare resource utilization
  • Have greater competence related to
    • Applying recommendations for influenza antiviral therapy and prophylaxis in children
    • Applying recommendations for influenza antiviral therapy and prophylaxis in adolescents
    • Applying recommendations for influenza antiviral therapy and prophylaxis in high-risk adults


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Charles Vega, MD

    Clinical Professor of Family Medicine
    University of California, Irvine
    Irvine, California

    Disclosures

    Charles Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson

  • Jeff Goad, PharmD, MPH, FAPhA, FISTM, CTH

    Professor and Associate Dean
    Office of Academic Affairs
    Department of Pharmacy Practice
    Chapman University School of Pharmacy
    Irvine, California

    Disclosures

    Jeff Goad, PharmD, MPH, FAPhA, FISTM, CTH, has the following relevant financial relationships:
    Consultant or advisor for: Emergent BioSolutions; Seqirus; Takeda; Valneva
    Speaker or member of speakers bureau for: Merck

  • Ravi Jhaveri, MD

    Professor of Pediatrics
    Northwestern University Feinberg School of Medicine
    Division of Pediatric Infectious Diseases
    Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois

    Disclosures

    Ravi Jhaveri, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Dynavax Technologies; Seqirus

  • Andrew Pavia, MD

    George and Esther Gross Presidential Professor of Pediatrics and Medicine
    University of Utah
    Chief, Division of Pediatric Infectious Diseases
    Salt Lake City, Utah

    Disclosures

    Andrew Pavia, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline

  • Ruth Carrico, PhD, DNP, APRN, CIC, FSHEA, FNAP, FAAN

    Professor, Division of Infectious Diseases
    University of Louisville School of Medicine
    Executive Director, Norton Infectious Diseases Institute
    Norton Healthcare
    Louisville, Kentucky

    Disclosures

    Ruth Carrico, PhD, DNP, APRN, CIC, FSHEA, FNAP, FAAN, has the following relevant financial relationships:
    Consultant or advisor for: Janssen; Johnson & Johnson; Moderna; Novavax; Pfizer; Sanofi
    Speaker or member of speakers bureau for: Pfizer; Sanofi
    Research funding from: Pfizer; Sanofi

Editor

  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.00 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-22-215-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Influenza Across the Ages: Tailoring Antiviral Therapy and Prophylaxis

Authors: Charles Vega, MD; Jeff Goad, PharmD, MPH, FAPhA, FISTM, CTH; Ravi Jhaveri, MD; Andrew Pavia, MD; Ruth Carrico, PhD, DNP, APRN, CIC, FSHEA, FNAP, FAANFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/13/2022

Valid for credit through: 7/13/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Recap of Current Flu and COVID-19 Prevalence and Trends

Dr Vega introduces the program by reviewing the most recent data on influenza epidemiology.
Charles Vega, MD

Antiviral Agents: Pharmacology and Healthcare Resource Utilization Outcomes

In this section, Dr Goad provides an overview on the mechanism of action of current antiviral agents, and how they may impact flu-related complications in patients.
Jeff Goad, PharmD, MPH, FAPhA, FISTM, CTH

Flu and Children: Antiviral Therapy and Prophylaxis

Dr Jhaveri notes particular considerations for treating and preventing influenza in young patients, many of which are considered at high-risk for complications.
Ravi Jhaveri, MD

Flu and Adolescents: Antiviral Therapy and Prophylaxis

In this section, Dr Pavia discusses treating and preventing influenza in adolescents, a group often overlooked when considering flu-related complications.
Andrew Pavia, MD

Flu and High-Risk Adults: Antiviral Therapy and Prophylaxis

Dr Carrico concludes this program with some considerations for treating and preventing influenza among high-risk adults, including those with non-age-related risk factors.
Ruth Carrico, PhD, DNP, APRN, CIC, FSHEA, FNAP, FAAN